Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia

L. Chap, G. Schiller, S. D. Nimer

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


GM-CSF has been used successfully in autologous BMTs, and more recently in patients undergoing allogeneic BMT, for acute or chronic leukemia. We report two patients with hepatitis-related aplastic anemia who received recombinant human GM-CSF following HLA-identical sibling allogeneic BMTs. Both patients were conditioned with CY 200 mg/kg given over 4 days and received GM-CSF at 250 μg/m2 beginning 6 h after marrow infusion and continuing daily until the absolute neutrophil count was > 1.0 X 109/l for 2 days. Both patients had prompt engraftment, achieving an absolute neutrophil count of > 0.5 X 109/l on day 13. Neither patient had side-effects attributable to the GM-CSF although one patient developed severe acute GVHD after the cessation of GM-CSF therapy. Our experience suggests that GM-CSF can be safely used in aplastic anemia patients undergoing BMT and that GM-CSF may be useful to decrease the incidence of graft failure associated with less intensive conditioning regimens.

Original languageEnglish (US)
Pages (from-to)173-175
Number of pages3
JournalBone Marrow Transplantation
Issue number2
StatePublished - Jan 1 1993
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia'. Together they form a unique fingerprint.

Cite this